Learn More
About Kleanthi Dx
Kleanthi Diagnostics, LLC is a biotechnology company involved in developing diagnostic tools for oxidation-related diseases. The company was co-founded by professors Sotirios Tsimikas and Joseph L. Witztum.
Kleanthi Diagnostics focuses on creating and utilizing biomarkers related to oxidized lipoproteins, which play a significant role in conditions like atherosclerosis, aortic stenosis, neurodegenerative diseases, and age-related inflammatory conditions.
Tsimikas and Witztum have leveraged their expertise in oxidative stress and immune response to develop innovative diagnostics that can identify and monitor diseases linked to oxidative damage. Their work includes the development of unique monoclonal antibodies targeting phosphocholine-containing oxidized phospholipids, which have shown promise in ameliorating various inflammation-related conditions.
Kleanthi benefits from the extensive research and numerous patents held by their founders, contributing significantly to advancements in cardiovascular and metabolic disease diagnostics.
FAQs
What kind of tests do you provide?
You can view our OxPl-apoA and OxPl-apoB test kits on our products page with a detailed description of each.
Are there studies or research papers published on the tests that Kleanthi Diagnostics provides?
You can view our premier white paper in collaboration with MedPace for more information. You can also view our studies page for a list of other studies that prove our tests.
Where can I get this test done?
Our tests are available for clinical and research purposes. Please reach out to our clinical collaborators if you are interested in getting this test done as a patient.
Who are the founders?
Professors Sotirios Tsimikas and Joe Witztum each have over 40 years of experience in the field of medicine. Their collective knowledge has created a top of the line assay for measuring signs of heart disease and related conditions. You can view detailed descriptions of each founder on the team page.